Contributors to Volume 36

A

Aach, R.D. ... 776
Abels, R.I. ... 29
Agosti, S.J. ... 533
Ahmed, M.M. ... 339
Akamatsu, S. ... 286(L)
Ala, F.A. ... 339
Alami, S.Y. ... 286(L)
Alexander, S.S. ... 45
Allain, J.P. ... 401, 476(L)
Allan, H. ... 691
Allen, D.D. ... 109
Allen, J. ... 481, 802
Almeida-Neto, C. ... 969
Aloysius, S. ... 401
Alvarez, F. ... 794
Alvarez-Mon, M. ... 463
Ambruso, D.R. ... 133
Anderlini, P. ... 590
Andersen, J.W. ... 21, 782
Anderson, J.K. ... 296
Anderson, K.C. ... 21, 117, 160, 782, 904
Armstrong, K.S. ... 1016
Arndt, P. ... 351
Aster, R.H. ... 296, 331, 895
Aston, S. ... 943
Atrah, H.I. ... 339
AuBuchon, J.P. ... 222, 755
Audat, F. ... 734
Augustyniak, L. ... 86(L)
Austin, E. ... 432
Axcell, T.J. ... 699
Ayash, L.J. ... 160
Azar, N. ... 552

B

Bae, S. ... 860
Bahl, C. ... 581(L)
Bajardi, S.E. ... 86(L)
Baker, K. ... 339
Balducci, L. ... 140
Bandarenko, N. ... 668(L)
Barbara, J.A.J. ... 401
Barbosa, L.H. ... 776
Bargay, J. ... 794
Baril, L. ... 707
Barker, L.F. ... 768(E)
Barrett, B.B. ... 21
Bartholeyns, J. ... 328
Bartlett, R.H. ... 61
Bass, D. ... 681
Beaton, M. ... 938(L)
Beckers, E.A.M. ... 104, 478(L), 506, 567
Bell, E.F. ... 873
Ben-Hur, E. ... 543, 743
Benkosky, S.L. ... 974
Benson, K. ... 140, 533, 904
Bentley, S.A. ... 476(L)
Berger, T.A. ... 318
Berlin, G. ... 714
Bertholf, M.F. ... 521
Bertolini, F. ... 128
Besalduch, J. ... 794
BEST Working Party of the ISBT ... 11, 128
Bettigole, R. ... 847(L)
Bierling, P. ... 328
Billups, L.C. ... 318
Biondi, C. ... 191(L)
Biswas, R. ... 194(BR)
Blanchard, ... 421
Blumenfeld, O.O. ... 719
Blundell, E.L. ... 296
Böck, M. ... 952
Bofill, C. ... 822
Bolgiano, D.C. ... 29
Boudifa, A. ... 552
Bowman, C.A. ... 985
Brady, K.A. ... 314
Brand, A. ... 438
Brandwein, H. ... 11, 939(L)
Bray, G. ... 358
Brecher, M.E. ... 476(L), 668(L), 948
Bremme, K. ... 500
Brettler, D.B. ... 358
Briët, E. ... 438
Bromelow, I. ... 432
Brooks, J.P. ... 739
Brossard, Y. ... 328
Brown, A.E. ... 398
Brünner, N. ... 960
Bryant, J.A. ... 559
Bryant, S. ... 144
Bubel, S. ... 445
Buchanan, I. ... 547
Buchholz, D.H. ... 296
Buckwalter, C. ... 358
Bumgarner, D.J. ... 481
Bundy, K. ... 487
Burger, S.R. ... 798
Burghoffer, B. ... 734
Burmeister, L.F. ... 873
Busch, M.P. ... 37, 45, 203, 232, 398,581(L), 854
Butch, S.H. ... 61
Butler, G. ... 487

C

Cabanela, M.E. ... 144
Calmann, M. ... 478(L)
Carrington, J.D. ... 854
Carven, J.H. ... 1000
Case, J. ... 1034(L)
Centers for Disease Control and Prevention/Bronx-Lebanon Hospital Center HIV Serosurvey Team ... 731
Chambers, L.A. ... 150
Chamone, D.F. ... 969
Champagne, K. ... 384(L)
Champlin, R. ... 590, 910
Chan, A.H.C. ... 347
Chan, J.C.M. ... 347
Chan, K.-W. ... 590
Chan, M.W.K. ... 347
Chao, F.C. ... 536
Chapman, R.H. ... 521
Chaudhry, V.P. ... 848(L)
Chen, P.-M. ... 685
Cheng, G. ... 347
Chester, M.A. ... 309
Chiafari, F.A. ... 259
Chiavetta, J.A. ... 699
Chiu, D.S.M. ... 347
Choy, F.M.F. ... 347
Christensson, B. ... 500
Christensson, M. ... 500
Christie, B. ... 665, 900
Chung, A.S.M. ... 347
Churchill, W.H. ... 521
Clay, K.L. ... 133
Clay, M.E. ... 596, 601
Clement, L.T. ... 168
Cliquet, M.G. ... 969
Clivillé, X. ... 822
Co, A. ... 351
Co Chien, H. ... 232
Cobain, T.J. ... 386(L)
Coghlan, G. ... 419
Cohen, D.M. ... 150
Collier, A. ... 854
Colman, R.W. ... 939(L)
Combest, T.G. ... 739
Combs, M.R. ... 481, 802
Connor, J. ... 691
Cooke, E. ... 879
Cooley, M.A. ... 559
Coral, F.S. ... 782
Corash, L. ... 406
Cordle, D.G. ... 873
Costagliola, D. ... 191(L)
Cotorruelo, C. ... 191(L)
Cottler-Fox, M. ... 985
Cowan, M.J. ... 314
Creger, R.J. ... 789
Crosson, J.T. ... 216
Currie, L.M. ... 691
Curtis, B.R. ... 331, 895
Cuypers, H.T.M. ... 344

Contributors to Volume 36

A

Aach, R.D. ... 776
Abels, R.I. ... 29
Agosti, S.J. ... 533
Ahmed, M.M. ... 339
Akamatsu, S. ... 286(L)
Ala, F.A. ... 339
Alami, S.Y. ... 286(L)
Alexander, S.S. ... 45
Allain, J.P. ... 401, 476(L)
Allan, H. ... 691
Allen, D.D. ... 109
Allen, J. ... 481, 802
Almeida-Neto, C. ... 969
Aloysius, S. ... 401
Alvarez, F. ... 794
Alvarez-Mon, M. ... 463
Ambruso, D.R. ... 133
Anderlini, P. ... 590
Andersen, J.W. ... 21, 782
Anderson, J.K. ... 296
Anderson, K.C. ... 21, 117, 160, 782, 904
Armstrong, K.S. ... 1016
Arndt, P. ... 351
Aster, R.H. ... 296, 331, 895
Aston, S. ... 943
Atrah, H.I. ... 339
AuBuchon, J.P. ... 222, 755
Audat, F. ... 734
Augustyniak, L. ... 86(L)
Austin, E. ... 432
Axcell, T.J. ... 699
Ayash, L.J. ... 160
Azar, N. ... 552

B

Bae, S. ... 860
Bahl, C. ... 581(L)
Bajardi, S.E. ... 86(L)
Baker, K. ... 339
Balducci, L. ... 140
Bandarenko, N. ... 668(L)
Barbara, J.A.J. ... 401
Barbosa, L.H. ... 776
Bargay, J. ... 794
Baril, L. ... 707
Barker, L.F. ... 768(E)
Barrett, B.B. ... 21
Bartholeyns, J. ... 328
Bartlett, R.H. ... 61
Bass, D. ... 681
Beaton, M. ... 938(L)
Beckers, E.A.M. ... 104, 478(L), 506, 567
Bell, E.F. ... 873
Ben-Hur, E. ... 543, 743
Benkosky, S.L. ... 974
Benson, K. ... 140, 533, 904
Bentley, S.A. ... 476(L)
Berger, T.A. ... 318
Berlin, G. ... 714
Bertholf, M.F. ... 521
Bertolini, F. ... 128
Besalduch, J. ... 794
BEST Working Party of the ISBT ... 11, 128
Bettigole, R. ... 847(L)
Bierling, P. ... 328
Billups, L.C. ... 318
Biondi, C. ... 191(L)
Biswas, R. ... 194(BR)
Blanchard, ... 421
Blumenfeld, O.O. ... 719
Blundell, E.L. ... 296
Böck, M. ... 952
Bofill, C. ... 822
Bolgiano, D.C. ... 29
Boudifa, A. ... 552
Bowman, C.A. ... 985
Brady, K.A. ... 314
Brand, A. ... 438
Brandwein, H. ... 11, 939(L)
Bray, G. ... 358
Brecher, M.E. ... 476(L), 668(L), 948
Bremme, K. ... 500
Brettler, D.B. ... 358
Briët, E. ... 438
Bromelow, I. ... 432
Brooks, J.P. ... 739
Brossard, Y. ... 328
Brown, A.E. ... 398
Brünner, N. ... 960
Bryant, J.A. ... 559
Bryant, S. ... 144
Bubel, S. ... 445
Buchanan, I. ... 547
Buchholz, D.H. ... 296
Buckwalter, C. ... 358
Bumgarner, D.J. ... 481
Bundy, K. ... 487
Burger, S.R. ... 798
Burghoffer, B. ... 734
Burmeister, L.F. ... 873
Busch, M.P. ... 37, 45, 203, 232, 398,581(L), 854
Butch, S.H. ... 61
Butler, G. ... 487

C

Cabanela, M.E. ... 144
Calmann, M. ... 478(L)
Carrington, J.D. ... 854
Carven, J.H. ... 1000
Case, J. ... 1034(L)
Centers for Disease Control and Prevention/Bronx-Lebanon Hospital Center HIV Serosurvey Team ... 731
Chambers, L.A. ... 150
Chamone, D.F. ... 969
Champagne, K. ... 384(L)
Champlin, R. ... 590, 910
Chan, A.H.C. ... 347
Chan, J.C.M. ... 347
Chan, K.-W. ... 590
Chan, M.W.K. ... 347
Chao, F.C. ... 536
Chapman, R.H. ... 521
Chaudhry, V.P. ... 848(L)
Chen, P.-M. ... 685
Cheng, G. ... 347
Chester, M.A. ... 309
Chiafari, F.A. ... 259
Chiavetta, J.A. ... 699
Chiu, D.S.M. ... 347
Choy, F.M.F. ... 347
Christensson, B. ... 500
Christensson, M. ... 500
Christie, B. ... 665, 900
Chung, A.S.M. ... 347
Churchill, W.H. ... 521
Clay, K.L. ... 133
Clay, M.E. ... 596, 601
Clement, L.T. ... 168
Cliquet, M.G. ... 969
Clivillé, X. ... 822
Co, A. ... 351
Co Chien, H. ... 232
Cobain, T.J. ... 386(L)
Coghlan, G. ... 419
Cohen, D.M. ... 150
Collier, A. ... 854
Colman, R.W. ... 939(L)
Combest, T.G. ... 739
Combs, M.R. ... 481, 802
Connor, J. ... 691
Cooke, E. ... 879
Cooley, M.A. ... 559
Coral, F.S. ... 782
Corash, L. ... 406
Cordle, D.G. ... 873
Costagliola, D. ... 191(L)
Cotorruelo, C. ... 191(L)
Cottler-Fox, M. ... 985
Cowan, M.J. ... 314
Creger, R.J. ... 789
Crosson, J.T. ... 216
Currie, L.M. ... 691
Curtis, B.R. ... 331, 895
Cuypers, H.T.M. ... 344

D

Danielson, C.F.M. 263
Daub, J. 725
Davenport, R. 707
Davidson, F. ..... 478(L), 547
Davidson, S. ..... 938 (L)
Davis, J.T. 150
de Angelis, V. 891
Decary, F. ..... 1035(L)
De Leon-Fernandez, M. 5
Delage, G. ..... 1035(L)
de la Serna, J. 463
DeLoughery, T.G. 827
de Marco, L. 891
Demetri, G.D. 160
Dempesy, D. 456
Denomme, G. 805
DePalma, L. ..... 10(E)
Desmond, M.J. 626, 628, 633, 640, 644
Devine, P. 375
Dickey, W.O. 133
Dickinson, J. ..... 86(L)
Di Rosso, A. ..... 386(L)
Dittmann, J. 250
Dodd, R.Y. 45
Domingo, C.J. 725
Dondero, T.J. 398
Dorazio, D. 860
Dorliach-Llacer, P. 969
Dow, B.C. ..... 478(L), 547
Duc, A. 124
Duedari, N. 328
Duerstein, S. 681
Dumont, L.J. 11
Dupuy-Montbrun, M.-C. 124
Durán, M.A. 794
Dutcher, J.P. 5
Dybkjær, E. 960
Dzik, W. 421
Dzik, W.H. 11

E

Eastlund, T. 900
Eble, B.E. 406
Echevarría, J.M. 725
Eckels, D.D. 836
Edvardsen, L. 960
Ehrenforth, S. ..... 84(L)
Eiber, G. 1009
Eickhoff, C.E. 160
Elghouzzi, M.-H. 124
Elias, A.D. 160, 782
Elola, C. 725
Eluf-Neto, J. 969
Ende, N. ..... 288(L)
Endean, D.J. 495, 895
Entelmann, M. 445
Ernst, J. 731
Espinosa, M.T.F. 789
Esquivel, C. 552
Evans, R.W. ..... 671(E)
Eyster, M.E. 928

F

Faas, B.H.W. 506, 567
Fan, T.C.W. 347
Fautsch, S.K. 798
Federowicz, I. 21
Filo, R.S. 263
Finberg, R.W. 782
Finlayson, J.S. 770
Fischer, G.F. 426
Flanigan, T.P. 854
Fletcher, A. 559
Flomenberg, P. 836
Follett, E.A.C. ..... 478(L), 547
Foresto, P. ..... 191(L)
Foulis, P.R. 533
Fournel, J.J. 552
Fox, M.A. 644
Fox, R. 789
Fraser, I.D. 296
Fratantoni, J.C. 770
Freedman, J. 699
Fretz, C. 552
Fried, M.R. 187, 900
Friedman, H.D. 460
Friedman, L.I. 335, 456
Furmanski, M. 351

G

Galacki, D. 879
Galbany, J. 822
Galel, S.A. 227
Gallin, J.I. 1009
Galmés, A. 794
Garcea, F. 322
Garcia Rosasco, M. ..... 191(L)
Garratty, G. ..... 192(L), 351
Geha, R. 879
George, J.R. 398
George, V.M. 335
Georges, D. 860
Gernsheimer, T. 854
Gerson, S.L. 575
Gilboa-Garber, N. 113
Gilcher, R.O. 232
Gill, J.C. 836
Gillespie, T.W. 611
Gillon, J. 626, 628, 633, 640, 644
Gilsanz, F. 463
Gingrich, R. 53
Glassman, A.B. 904
Godeau, B. 328
Goldman, M. ..... 1035(L)
Goldstein, R. 375
Gomperts, E.D. 358
Goodnight, S.H. 827
Goodnough, L.T. 29, 521
Gorlin, J.B. ..... 879, 938(L)
Gottlieb, P. 743
Gough, D. 339
Grauer, M.T. 450
Greeno, E.W. 71
Greenwalt, T.J. 296
Greenwell, P. 994
Gregoretti, S. 57
Greppi, N. 322
Grindon, A.J. ..... 88(BR)

H

Haass, A. 450
Hamilton, R.A. 533
Hannoush, H.M. ..... 286(L)
Hausman, E. 421
Hawker, R.J. ..... 1033(L)
Hazenberg, C.A.M. ..... 478(L)
Heaton, W.A. 751
Heckel, L. 140
Hedberg, S.L. 296
Heim, M.U. 952
Hellman, R.M. 29
Hemophilia Malignancy Study 681
Herr, G.P. 168
Herst, R. 699
Heshmati, F. 734
Hessner, M.J. 495, 895
Hewlett, I.K. ..... 194(BR)
Hibberd, P.L. 1000
Hillyer, C.D. 611
Hines, D. 904
Hines, D.M. 375
Hino, K. ..... 669(L)
Hirschler, N.V. 575
Ho, C.H. ..... 290(L)
Hoffstadter, L.K. 375
Holland, P.V. 854
Hollinger, F.B. 776
Hom, E. 948
Hopkins, D. 832
Horlocker, T.T. 144
Horowitz, B. 743
Horsewood, P. 805
Houranieh, A.M. 536
Hu, D.J. 398
Hu, H.-Y. 685
Huang, C.-H. 719
Huang, W. 776
Huizinga, T.W.J. 438
Hume, H.A. 904
Humpe, A. 250
Humphreys, D. 879
Hunt, W.C. 674
Hutchinson, F. 339

I

Ilstrup, S. 596
Ilstrup, S.J. 71

Immelmann, A. 866
Inderbitzen, P.E. ..... 84(L)
Irwin, K.L. 731
Ishikawa, M. ..... 669(L)
Issitt, P.D. ..... 97(E), 481, 761(L), 802

J

James, D.S. 674
James, T. 873
Janot, C. 394
Janssen, R. 731
Jaszcz, W. 601
Jaulmes, D. 552
Jensen, N.J. 216
Johnson, C.A. 133
Johnson, K. 873
Johnston, M.F.M. 29
Jordan, J.A. 238
Joseph-Steiner, J. ..... 84(L)
Joven, J. 822
Juji, T. ..... 846(L)

K

Kagen, L.R. 296
Kai, M. 398
Kalmin, N.D. ..... 582(L)
Kao, K.-J. 818
Kao, K.J. 521
Kashkari, M. 854
Katz, L.M. ..... 582(L)
Kawahata, T. ..... 475(L)
Kazemi, M. 358
Kehlet, H. 960
Kelton, J. 805
Kempf, C. 866
Kennedy, M. 854
Kent, P. 879
Kessler, C.M. ..... 86(L)
Key, N.S. 467, 900
Kfoury-Baz, E. ..... 286(L)
Khorshidi, M. 5
Kibbi, A.G. ..... 286(L)
Killian, D. ..... 476(L)
Kim, B.K. 536
Kirchhoff, L.V. 227
Kirchner, H. 445
Kirkland, A. 481
Kishi, K. ..... 286(L)
Kitchen, A. 401
Klarmann, D. ..... 84(L)
Klein, H.G. 955
Kleinman, S.H. 37, 232
Kline, L. 335, 456
Klüter, H. 445
Knafl, P. 61
Knapp, W. 268
Koch, W.C. 238
Kochesky, R. ..... 581(L)
Koerner, T.A.W. 521
Köhler, M. 250, 426
Konrad, M.W. 536
Koontz, F. 53
Körbling, M. 590
Korelitz, J.J. 203, 232
Kotz, R. 155
Kreuz, W. ..... 84(L)
Kuan, H.-L. 818
Kumar, P.N. 854
Kumpel, B.M. 432
Kurz, R.W. 155

L

Lackritz, E. 398
Lam, S.T. 347
Lane, B. ..... 384(L)
Lane, T.A. ..... 64, 585(E), 854
Laycock, M.E. 37
Layug, L. 45
Lazarus, H.M. 789
Leaute, J.-B. 328
Leavitt, A.D. 314
LeBien, T.W. ..... 197(E)
Lecchi, L. ..... 937(L)
Ledent, E. 714
Lederman, M.M. 860
Lee, J.C.-I. 685
Lee, J.F.L. ..... 386(L)
Lee, L.L.L. 37
Lee, S. 490
Lee, S.R. ..... 478(L), 581(L)
Lefrère, J.-J. 124
Lefrère, J.J. 394, 734
Legler, T.J. 250, 426
Leitman, S.F. 1009
Lelie, P.N. 344
Lenfant, C. 82, 935
León, P. 725
Leonard, K. 1009
Le Pont, F. ..... 191(L)
Lerable, J. 734
Leroux-Roels, G. 552
Levene, C. 113
Leveton, L.B. 919
Levitsky, S. ..... 845(L)
Liang, F.H. 536
Lichtiger, B. 590
Liebler, J.M. 827
Ligthart, P. 104, 567
Limpakarnjanarat, K. 242
Lin, D.-T. 818
Lin, J.-S. 685
Linden, J.V. 375
Lippert, L.E. 318
Littenberg, B. 222
Liu, E. 64
Livesey, S.A. 691
Llobet, X. 822
Lloyd-Evans, P. 432
Loiseau, P. 394
Long, A. ..... 1035(L)
López, J.A. 725
Luban, N.L.C. ..... 10(E)
Lubenko, A. 994
Lublin, D.M. ..... 293(E)
Ludwig, G.A. 873
Lui, Y.K. 347
Lunel, F. 552
Lusher, J. ..... 86(L)
Lustigman, S. 543
Lyman, G.H. 140
Lynch, T.J. 770
Lynen, R. 250

M

Madurga, M. 725
Maertens, G. 552
Magsamen, M.J. 943
Mailhot, E.A. 974
Mair, B. 533
Mair, D.C. 948
Majdic, O. 268
Mak, K.H. 994
Malech, H.L. 1009
Mallory, D.M. 256
Maloney, R. ..... 386(L)
Mannino, F.L. 64
Marani, T.M. 1016
Marcellin, P. 394
Margolis-Nunno, H. 743
Mariotti, M. 394
Martinot-Peignoux, M. 394
Mascaró, M. 794
Mastro, T.D. 242
Matamoros, N. 794
Matsuo, K. 809
Maybee, D.A. 318
Mayer, A. 969
Mayr, W.R. 250, 426
Mazzucato, M. 891
McAlpine, P.J. 419
McCarthy, L.J. 263
McCarthy, P. 575
McCullough, J. ..... 589(E), 596, 601, 798, 1019
McCurdy, P.R. 854
McCutchan, F.E. 398
McDonough, W. 674
McFarland, J.G. 495
McGurk, S. 521
McKeown, I. 419
McVay, P.A. ..... 761(L)
Mechanic, S. 707
Mellors, J.W. 854
Melroy-Carawan, H. 481, 802
Mendelson, D.N. ..... 382(L)
Mendonça, M.C. 969
Menitove, J.E. 296
Miller, J. 873
Miller, P. 590
Milo, K.M. 140
Minniti, C. 1016
Mitchell, S.G. ..... 1033(L)
Mitsunaga, S. ..... 846(L)

Moertel, C.L. 467
Mohandas, K. 854
Moltó, L. 463
Moore, R.H. 318
Moore, S.B. ..... 487, 852(E)
Morand-Joubert, L. 734
Morey, M. 794
Morgenthaler, J.-J. 866
Mori, H. ..... 475(L)
Mori, K. ..... 669(L)
Morimoto, M. ..... 475(L)
Mosley, J.W. 776
Moulds, J.J. 362
Moulds, J.M. 362, 517
Moulds, M.K. ..... 384(L)
Mrowiec, Z.R. 5
Mudido, P.M. 860
Muggenthaler, K.-H. 952
Mullane, S. ..... 938(L)
Mullin, G.T. 900
Munro, H. 547
Murphy, S. 128, 751
Muylle, L. 886

N

Nadler, L.M. 782
Naiman, J.L. 974
Naime, D. 490
Nakagami, T. ..... 475(L)
Nakashima, H. ..... 669(L)
Nassif, R.E. ..... 286(L)
Neff, T.P. 109
Nelson, K.E. 242
Nemo, G.J. 232, 776
Nemunaitis, J.J. 943
Ness, P.M. 1016
Neumeyer, H. 250
Newman, B.H. 209, 213
Nielsen, H.J. 960
Nishimura, M. ..... 846(L)
Nishiyama, Y. ..... 669(L)
Noonan, M. 460
Norën, P.A. 168
Norfleet, F. 590
Norris, S.S. 109
Novotny, V.M.J. 438
Nowicki, B.J. 362
Nowicki, M.J. 776
Nowicki, S. 362
Nuttall, G.A. 144

O

Oberman, H.A. 61, 904
O'Brien, W.A. 860
O'Donnell, J.A. 263
Oetjen, J. 743
Oh-kawara, H. ..... 286(L)
Ohno, H. ..... 475(L)
Ohnoki, S. 813
Ohto, H. 117, 426
Okamoto, H. ..... 669(L), 937(L)
Oki, A. 966
Oki, M. 966
Oksenhendler, E. 328
Okubo, Y. ..... 286(L), 490, 813
Okumura, Y. 966
Oldham, F. 596
Oldham, F.B. 601
Oleksowicz, L. 5
Oliver, Jr., W.C. 144
Olivo, N. 731
Olson, J.D. 521
Olsson, M.L. 309
Omar, A. 866
Osada, K. ..... 937(L)
Otake, T. ..... 475(L)
Overbeeke, M.A.M. ..... 104, 478(L), 506, 567
Owen, H. ..... 668(L)
Owen, H.G. 948
Ownby, H.E. 37, 232

P

Padley, D. 53
Pamphilon, D.H. 296
Panzer, S. 250, 426
Parker, M.E. ..... 288(L)
Paterson, A.J. 133
Pau, C.-P. 37
Pau, C.P. 398
Pedersen, A.N. 960
Peetermans, M.E. 886
Pepper, R. 506
Peró, A. 822
Perry, E.H. 71
Perry, E.S. 318
Peterson, J. ..... 581(L)
Petit, J.C. 734
Petrik, J. 401
Petzoldt, M.L. 601
Philipps, S. 419
Phillips, P. ..... 384(L)
Pies, A. 250
Pindur, G. 450
Pisciotto, P.T. 904
Pivacek, L.E. 303
Polesky, H.F. ..... 392(E)
Pollard, R.B. 854
Poole, J. 994
Poortenga, M. ..... 938(L)
Popovsky, M.A. 21, 456, 470, 904
Porcelijn, L. 104
Postoway, N. 375
Pradella, P. 891
Price, T.H. 29
Pringle, T.C. 335
Przepiorka, D. 590
Puszkin, E.G. 5

Q

Quintana, R. 674

R

Rabinowitz, W.M. 456
Racca, A. ..... 191(L)
Ragni, M.V. 238, 681
Ralph, H. 719
Ravera, N. 394
Rayfield, M.A. 398
Read, E.J. ..... 1(E)
Rearden, A. 979
Rebulla, P. ..... 11, 322, 751, 937(L)
Redman, C. 490
Reed, D. 734
Reesink, H.W. 344
Reeves, I. 401
Reid, D.M. 809
Reid, M. 490
Reid, M.E. 512, 719
Reimert, C.M. 960
Reisner, R. 487
Rentsch, M. 866
Reppucci, A.J. 296
Retrovirus Epidemiology Donor Study 37, 203
Ribeiro, A. 559
Riggert, J. 250
Ritz, J. 782
Rizzo, R.J. 521
Robinette, D. 989
Robinson, R. 743
Rodberg, K. 351
Rosenfeld, C.S. 943
Rosenthal, N.S. 575
Roudot-Thoraval, F. 734
Roush, G.R. 575
Rouzioux, C. ..... 191(L)
Rowe, K.E. 517
Roy, G. ..... 1035(L)
Rubiez, N.G. ..... 286(L)

S

Sabbioneda, L. 322
Sabino, E.C. 969
Sacher, R.A. 29
Saeed, S.M. 209
Saéz-Alquézar, A. 969
Salata, K.F. 318
Salles, N.A. 969
Salmerón, F. 725
Salpétrier, J. 124
Sandler, S.G. ..... 256, 382(L), 1016
Sans, T. 822
Santrach, P.J. 144
Sato, T. 966
Sawanpanyalert, P. 242
Sayers, M.H. 932
Sayre, K.R. 45
Schable, C. 398, 731
Schaeffer, A. 328
Schimrigk, K. 450
Schleinzer, W. ..... 849(L)

Schmidt, P.J. ..... 287(L)
Schmidt, U. 952
Schochetman, G. 398
Schreiber, G.B. 37
Schwameis, E. 155
Schwartz, G.N. 160
Scofield, T.L. 187
Scott, C.F. ..... 939(L)
Seed, C.R. ..... 386(L)
Sela, R. 113
Seno, T. ..... 286(L)
Seong, D. 590
Serody, J. ..... 668(L)
Shafer, A.W. 209
Shankar, R.A. 168
Shanwell, A. 500
Shaughnessy, W.J. 144
Shea, T. ..... 668(L)
Shea, T.C. 948
Shibata, Y. 813
Shibata, H. 813
Shieh, D.-C. 818
Shigehisa, T. ..... 475(L)
Shimizu, M. ..... 937(L)
Shopnick, R.I. 358
Silliman, C.C. 133
Simmonds, P. 547, 725
Simó, J.M. 822
Simonds, V. 827
Simsek, S. 506, 567
Singbartl, G. ..... 849(L)
Singbartl, K. ..... 849(L)
Singh, S. ..... 848(L)
Sirchia, G. ..... 322, 388(E), 937(L)
Sistonen, P. 490
Skov, P.S. 960
Slichter, S.J. 75
Sloand, E.M. 955
Smetannikov, Y. 832
Smith, D.M., Jr. ..... 765(E)
Smith, J. 596, 601, 805, 1016
Smith, J.W. 37
Smith, K.J. 674
Snyder, E.L. ..... 296, 707, 765(E)
Soloway, H.B. ..... 382(L)
Son, S. 490
Sox, Jr., H.C. 919
Spritzler, J. 860
Spruill, C. 398
Steane, E.A. ..... 200(E)
Steane, S.M. ..... 200(E)
Steffan, A. 891
Stevens, C.E. 776
Stockenhuber, F. 155
Stockinger, H. 268
Storry, J.R. 512, 719
Stoto, M.A. 919
Stram, D.O. 776
Strauss, R.G. 53, 873
Stroncek, D.F. 168, 187, 467, 596, 601, 798, 1009
Stuyver, L. 552
Sudakevitz, D. 113
Sugasawara, E.J. 974
Sunamoto, J. 966
Sundberg, J. 590
Surgenor, D.M. 521
Suzuki, K. 966
Swanson, J.L. ..... 187, 467, 85(L)
Swisher, S.N. 536

T

Tadokoro, K. ..... 846(L)
Tanaka, S. 813
Tankersley, D.L. 770
Taylor, E. 432
Tegtmeier, G. 45
Telen, M.J. ..... 97(E), 761(L)
Teramura, G. 75
Thauvin, M. 394
Thomas, M.J.G. 626, 628, 633, 640, 644
Thomson, A.R. 559
Thurman, G.W. 133
Tobler, L.H. ..... 581(L)
Tokunaga, K. ..... 846(L)
Toy, E.M. 575
Toy, P.T.C.Y. ..... 761(L)
Traver, M. 259
Treib, J. 450
Trich, M.B. 1016
Trigg, M.E. 53
Trimble, J. 256
Triulzi, D.J. 681
Tullis, J.L. 536
Turner, V.S. ..... 1033(L)
Tzeng, C.-H. 685

U

Uchida, S. ..... 846(L)
Ueba, N. ..... 475(L)
Urashima, M. 21
Uthaivoravit, W. 242

V

Valeri, C.R. 303
Valleron, A.J. ..... 191(L)
Valverde, J. ..... 191(L)
Vamvakas, E.C. 175, 879, 1000
van der Poel, C.L. 344
van der Schoot, C.E. 506, 567
van Doorn, R. 438
van Rhenen, D.J. 104, 506, 567
van Rooy, S.C. 699
VATS Group 854
Vermey, H. 104
Viele, M. 854
Vittecoq, D. 734
Voak, D. ..... 384(L), 994
Vogler, W.R. 29
von dem Borne, A.E.G.Kr. 104, 506, 567
Vrielink, H. 344

W

Wagner, S.J. 989
Wali, J.P. ..... 848(L)
Wall, A.J. 699
Wallace, E.L. 521
Wang-Rodriguez, J. 64, 979
Waxman, D.A. 213
Webb, I.J. 160, 782
Weber, J.T. 731
Weinstein, M.J. 770
Weinthal, J.A. 943
Weisdorf, D.J. 71
Wenk, R.E. 259
Wenzel, E. 450
Westgren, M. 500
Wheeler, C.A. 160
Whitbread, J. ..... 939(L)
Wiley, J. ..... 668(L)
Wilhelm, D. 445
Wilkinson, S.L. 109
Williams, A.E. 37, 203, 232, 398
Williamson, L.M. 401
Windhager, R. 155
Wong, H.F. 347
Woodson, R.D. 521
Wouters, E. 886
Wright, P. ..... 476(L)
Wu, X. 490
Wurnig, C. 155
Wylie, B.R. 559

X

Xu, W. 805

Y

Yamaguchi, H. 813
Yan, K.F. 994
Yanai, H. 242
Yang, B.-S. 818
Yang, L. 358
Yap, P.L. 547, 725
Yasuda, T. 966
Yazawa, S. ..... 286(L)
Yen-Lieberman, B. 860
Yomtovian, R. ..... 85(L), 575, 854
Yu, M. 955, 985
Yuan, F.F. 559
Yung, C.-H. 685

Z

Zaaijer, H.L. 344
Zelinski, T. 419
Zoubek, A. 155
Zuck, T.F. 232, 928
Zuckerman, D. 5

TRANSFUSION—VOLUME 36 (1996)
Subject Index

In the subject index, the page number refers to the first page of the communication in which the subject is addressed rather than to the specific page on which the referenced key words can be found. An "L" in parentheses following the page number indicates that the subject entry appeared in a letter to the editor; an "E" in parentheses indicates that the subject was discussed in an editorial; a "/" between numbers indicates on what page the correction for the subject entry appears.

In Volume 36 (1996), Number One (January) contains pages 1-96; Number Two (February), pages 97-196; Number Three (March), pages 197-292; Number Four (April), pages 293-387; Number Five (May), pages 388-480; Number Six (June), pages 481-584; Number Seven (July), pages 585-670; Number Eight (August), pages 671-764; Number Nine (September), pages 765-851; Number Ten (October), pages 852-942; Number Eleven/Twelve (November/December), pages 943-1053.

A

A428, search ..... 286(L)
A blood group antigens
  alleles 309
  extraction from liposomes 966
  individuals, *ABO*, polymorphisms 309
ABO
  fatal mistyping 351
  incompatibility, minor, BMT followed by hemolysis 71
ABO, polymorphisms in A individuals 309
abstracts, Consensus Conference on Autologous Transfusion 652
ACD-A 798
acid elution, HLA class I-eluted platelets 438
African Americans
  NA1/NA2 895
  Nak^a-negative platelet phenotype 331
AHTR, see transfusion reactions, acute hemolytic
AIDS, see also human immunodeficiency virus
  CMV and transfusion 681
  hemophiliacs, blood safety decisions, 1982–1986 928
  passive immunotherapy 734
AIHA, see anemia, autoimmune hemolytic
air embolism, red cell salvage 64
alanine aminotransferase (ALT)
  donor levels and HBV and NBNC hepatitis 776
  donor screening ..... 847(L)
albumin, AHG tests compared with PEG 487
allele-specific restriction analysis (ASRA)
  HPA-4 809
  HPA systems 1 to 5 genotyping 426
    after BMT 71
    and prewarmed tests ..... 192(L)
alloantibodies, autoadsorption for detection ..... 384(L)
alloanti-D, HDN and ..... 478(L)
allogeneic transfusion
  alternatives 629
  cost 649
  future 630
  indications 628
  risks 628
alloimmunization
  c(Rh4), frequency in R_1R_1 patients with anti-E ..... 85(L)
  granulocyte transfusions and 1009
  incidence 481
ALT, see alanine aminotransferase
American Association of Blood Banks (AABB)
  international blood banking and ..... 765(E)
  questionnaire on apheresis, blood collection, and transfusion-related activities 375
anaphylaxis, recombinant factor VIII treatment, and 358
anemia
  autoimmune hemolytic (AIHA)
    DAT-negative 463
    with reticulocytopenia, erythroid dysplasia, and an IgG2 autoanti-U 575
  carboplatin-induced immune hemolytic 1016
  chemotherapy-induced, prevention 155
  continuous reinfusion of whole blood, unprocessed 648
  hemostatic effect of red cell transfusion ..... 290(L)
  neonatal, TA-GVHD 117
angiotensin-converting enzyme inhibitor therapy, white cell-reduced plasma hypotensive reactions 900
ANH, see hemodilution, acute normovolemic
anti-Di^b 802
antibiotics, platelet increment posttransfusion and 952
antibodies
  platelet 75
  red cell
    anti-A 71
    anti-c ..... 85(L)
    anti-D ..... 97(E), 104, 432, 478(L), 500
    anti-Di^b 802
    anti-E ..... 85(L), 384(L)
    anti-Hr_o ..... 191(L)
    anti-K ..... 384(L)
    anti-Vw ..... 938(L)
    drug-dependent 187
    neutralization, of Knops system 517
    produced by
      persons with autoantibodies 481
      S–s– persons 512
antigens
  AnWj 369
  HIV 203
  neutrophil
    NA1/NA2 895

NB1 168
platelet 75
all systems 426, 813
HPA-4 system 809
Nak[a] 331
red cell
ABO 71, 309, 314, 351
acquired B 351
as receptors for bacteria and viruses ..... 293(E), 362
c ..... 84(L), 85(L)
comparison of tests to detect 487
D ..... 97(E), 104, 191(L), 314, 478(L), 506, 567, 761(L)
E ..... 85(L)
e ..... 191(L)
En(a) 512
Fr[a] 419
Fy6 421
G 506
He 719
in patients with autoantibodies ..... 384(L), 481
Kell system 490, 495
P 113
P_1 113
P^k 113
p 113
S 512, 719
s 512, 719
Sw[a] 419
U 512, 575, 719
antiglobulin test, direct (DAT)
autoadsorption 481
HLA-DQ6 frequency in DAT positive patients 979
negative in AIHA 463
PEG, compared with enzyme-based antibody tests 487
apheresis
AABB questionnaire 375
G–CSF-mobilized blood stem cells 590
PBPC content, G–CSF-stimulated normal donors 943
single-donor, platelet concentrates, vs random-donor whole blood 955
aprotinin, storage of buffy coat platelets 5
apyrase, storage of buffy coat platelets 5
arterial line placement in the critically ill, hemostatic defects and 827
ascorbic acid, storage of buffy coat platelets 5
Asian Indians, NA1/NA2 895
Asians, Nak[a]-negative platelet phenotype 331
AS-1 red cells, neonatal transfusions 873
assays, screening, anti-HCV 401
attitude
donors', self-exclusion, HIV 124
patients', home transfusion 140
Australia, national blood program 1019
Austria, national blood program 1019
autoadsorption
alloantibody detection ..... 384(L)
red cell autoantibodies and sera antibodies 481
autoantibodies
AIHA 575
HLA-DQ6 frequency in DAT-positive patients 979
mimicking 481
red cell
antibodies in sera 481
anti-Di[b] 802
autologous donation
adverse effects and contraindications 635
cost effectiveness 636
efficacy 634
infectious disease marker testing ..... 85(L)
low hematocrit, rHuEPO and 29
preoperative 633
rHuEPO, low-dose subcutaneous administration 822
severe outcomes ..... 761(L)
autologous transfusion 630
autologous transplantation, purging normal from malignant cells 910

B

B, blood group antigens
acquired, fatal ABO mistyping 351
extraction from liposomes 966
1B5, monoclonal antibody, NB1 and 168
B19, infection, hemophilia and 238
bacteria, blood groups as receptors 362
see also contamination; infection
barcodes, patient–blood unit identification 216
barrier system, cost-effectiveness in prevention of transfusion errors 222
bedside filters
component storage and 470
white cell reduction 322
BEST, see Biomedical Excellence for Safer Transfusion
biologic response modifiers, removal with bedside white cell-reduction filter 707
Biomedical Excellence for Safer Transfusion Working Party, guidelines for white cell-reduced blood components 11
bleeding, intraoperative, mathematical model for minimizing hemoglobin loss 832/1036
blood
banking ..... 582(L)
collection, AABB questionnaire 375
components, AABB questionnaire 375
groups
antigens ..... 293(E)
incidental receptors for viruses and bacteria 362
irradiation, TA-GVHD, neonatal 117
loss
mathematical model for minimizing hemoglobin loss 832/1036
reduction 629
monitoring system, NHF model ..... 86(L)
programs, national, developed countries 1019
safety
decisions, 1982-1986 ..... 919, 928
p24 antigen testing for blood safety ..... 191(L), 203, 382(L)
saline-adenine-glucose-mannitol, storage and bioactive substances 960
salvage, intraoperative, suction-induced hemolysis 57
stem cells, G–CSF mobilization and apheresis 590

supply, HIV 919, 925
utilization, extracorporeal membrane oxygenation therapy for adults 61
volume, donor tolerance to red cell donation 674
waste, multiply transfused premature infants 64
Blood Products Advisory Committee 928
Blood Safety Director ..... 582(L)
BMT, see bone marrow transplantation
bone marrow
alternative, G–CSF 590
bacterial contamination following processing 53
harvesting ..... 476(L)
reconstitution, PBPCs 611
transplantation (BMT)
circulating red cells 314
minor ABO incompatibility followed by hemolysis 71
same-donor peripheral buffy coat as 685
see also hematopoietic stem cell components
bone tumors, chemotherapy-induced anemia prevention 155
book reviews 88, 194
Bordetella pertussis, blood groups 362
BRAD-3, quantification of fetomaternal hemorrhage 432
Brazil, blood donors and risk of Chagas' disease 969
buffy coat, same-donor peripheral in relapsed acute leukemia 685

C

C1, inhibitor, pasteurized, HCV and ..... 84(L)
California, donor infection risk *Trypanosoma cruzi* 227
Canada
national blood program 1019
red cell use in Ontario hospitals 699
cancer
purging normal from malignant cells in autologous transfusion 910
recurrence, transfusion-associated, meta-analysis of randomized clinical trials 175
red cell salvage 647
carboplatin, immune hemolytic anemia and 1016
cardiac patients
autologous donation 635, 637
red cell salvage 645
CD directory, 1995 269
CD3
1995 directory, ... 269
donation, and normal ranges 559
CD4
1995 directory 269
donation, and normal ranges 559
CD8
1995 directory 270
donation, and normal ranges 559
CD19
1995 directory 271
donation, and normal ranges 559
CD34
cell lines, preparation and thawing 985
1995 directory 273
G–CSF effects 601
CD56
1995 directory 277
donation, and normal ranges 559
cell lines, CD34+ and CD34–, preparation and thawing for flow cytometry 985
cell saver, cost 649
Centers for Disease Control, HIV in the blood supply 925
Central America, donors and *Trypanosoma cruzi* 227
Chagas' disease, donors and risk 227, 969
chemokines
platelet concentrates, stored 445
removal with bedside white cell-reduction filter 707
chemotherapy
anemia prevention 155
carboplatin-induced immune hemolytic anemia 1016
PBPCs, mobilization and 160, 611
children see infants; pediatrics
Chinese
H-deficient phenotypes, Hong Kong 994
HLA-A*0207 frequencies 818
chloramphenicol-dependent antibody 187
chromosome 17q, Froese and Swann blood group polymorphism 419
citric acid, treatment of platelets ..... 388(E), 438
clinical decision making ..... 671(E)
clusters of differentiation (CD), 1995 directory ..... 197(E), 268
coagulation, HES and 450
coagulopathy
continuous reinfusion of whole blood, unprocessed 648
red cell salvage 646
Collaborative Hospital Transfusion Study, coronary artery bypass graft surgery, transfusion requirements 521
colony-forming units, bacterial contamination detection in platelet concentrates 989
colorectal cancer, transfusion and infection postsurgery .. 1000
complement
receptor 1 (CR1), neutralization of Knops system antibodies 517
removal with white cell-reduction filter 707
components 375
use in Ontario hospitals 699
concentrates, filtration of white cells from 714
white cell-reduced
BEST guidelines for process validation and process control 11
filtered before storage vs at bedside 470
transfusion reactions 21
computerization, patient–blood unit identification 216
Consensus Development Conference on Autologous Transfusion ..... 589(E), 625
containers
freezing, PBPCs 303
shipping, platelet components 335

contamination, bacterial 620
after donor call-back ..... 1035(L)
blood groups as incidental receptors 362
detection in platelet concentrates by swirling, pH, and glucose tests 989
PBPCs 782, 789
cord blood collection, safety ..... 937(L)
coronary artery bypass graft surgery, transfusion requirements 521
cost-effectiveness ..... 755, 849(L)
c(Rh4), alloimmunization in R_1R_1 patients with anti-E ..... 85(L)
Cromer blood group system 362
crossreactive epitope, HCV core antigen ..... 581(L)
cryoprecipitate, coronary artery bypass graft surgery transfusion requirements 521
cryopreservation, see also freezing
of PBPCs 303, 794, 985
cytokines
PBPC mobilization 611
platelet transfusions 886
purging normal from malignant cells in autologous transfusion 910
release, component storage and 470
cytomegalovirus (CMV)
AIDS and transfusion 681
hemotherapy for organ transplantation, institutional variation 263/764
VATS 854
cytotoxicity, natural killer cells in AIHA 463

D

D alloanti-, in $R_o^{Har}r$ subjects ..... 97(E), 104, 1034(L)
partial 761(L)
and *RHD* 567
7D8, monoclonal antibody, NB1 and 168
D–CE–D 567
decision making
analysis 755
clinical decision making ..... 671(E)
HIV in the blood supply 919, 928
depletion, purging normal from malignant cells in autologous transfusion 910
diagnosis-related group 106 and 107, coronary artery bypass graft surgery transfusion requirements 521
DIDS, see entry below
4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS), rouleaux formation and 109
directory for the human leukocyte clusters of differentiation, 1995 268
disease transmission, see infection, transfusion-associated
donors
ALT levels in ..... 847(L)
anti-HBc and retroviral infections 232
anti-HCV-positive, genotype prevalence 552
bacterial contamination after call-back ..... 1035(L)
Chagas' disease 227, 969
elderly as autologous 635
exposure limiting in premature infants 64
Gilbert's syndrome 974
HCV virus seroconversion 339
higher-risk, and new HIV test 203
HIV
deferral criteria, Thailand 242
positive, predonation interviews 124
IgG2 and IgA, coexistent deficiencies 256
indeterminate for anti-HIV-1 and anti-HIV-1/2 37
lymphocyte subsets, normal ranges of 559
multi-gallon ..... 288(L)
neurologic needle injury in 213
privacy during health history interviews 456
random- vs single-donor for platelet concentrates 955
reactions, severe ..... 287(L)
tolerance, red cell donations 674
Trypanosoma cruzi 227, 969
DQB1*0401 ..... 846(L)
DRB1*0405 ..... 846(L)
drug-related (chloramphenicol-dependent) antibody 187
Duffy glycoprotein, red cell chemokine receptor and Fy6 epitope 421

E

E and e antigen deletion in pregnancy ..... 191(L)
economics, clinical decision making and ..... 671(E)
effectors, second-messenger, recovery of platelets after storage 691
elderly, autologous donation 635
electrolyte solution, tissue culture media vs ..... 476(L)
electronic blood banking, for compatible blood during surgery 347
England, national blood program 1019
enzyme-linked immunosorbent assay (ELISA), HPA-1a (Pl^{A1})-negative donor platelets 805
equipment, red cell salvage 645
errors
autologous donation 636
red cell salvage 646
erythroid dysplasia, AIHA and 575
erythropoiesis, rHuEPO and 29
erythropoietin, recombinant human (rHuEPO)
autologous donation 29, 637, 822
chemotherapy-induced anemia prevention 155
PBPC mobilization 611
Escherichia coli, blood groups and 362, 367
Ewing's sarcoma, chemotherapy-induced anemia prevention 155
exchange transfusion
bone marrow transplantation with minor ABO incompatibility followed by hemolysis 71
neonatal, TA-GVHD 117
extracorporeal membrane oxygenation therapy for adults, blood utilization 61

F

factor VIII
HES and 450
recombinant, anaphylaxis following 358
factor IX inhibitor in plasma detects factor IX on red cells .. 467
fetomaternal incompatibility and ovum transplantation ..... 84(L)

fibrin sealant ..... 845(L)
filgrastim, see granulocyte–colony-stimulating factor
filtration 322, 707, 714
Finland, national blood program 1019
flow cytometry
CD34 cell lines, preparation and thawing 985
D antibodies in serum in pregnancy 500
fetomaternal hemorrhage, quantification of 432
HLA class I-eluted platelets 438
lymphocyte crossmatching 250
platelet crossmatching 250
flow rate, effect on filtration 470
fluid overload 629
Food and Drug Administration 919, 928
FR:SLC4A1 419
France
HCV IVIG 394
national blood program 1019
freezing, see also cryopreservation
rate-controlled, PBPCs 794
Froese blood group polymorphism 419
Fy6 epitope, chemokine receptor and 421

G

G epitope formation, Ser 103 involvement 506
G428, search ..... 286(L)
gastrointestinal symptoms, donors, bacterial
contamination after call-back ..... 1035(L)
G–CSF, see granulocyte–colony-stimulating factor
genes
frequencies
five ethnic groups 895
platelet antigens on GPIIIα 813
TA-GVHD ..... 846(L)
genetics, sibship determination in any two persons 259
genetic therapy, purging normal from malignant cells
in autologous transfusion 910
Gilbert's syndrome, icteric donor plasma 974
glucose tests, bacterial contamination detection in
platelet concentrates 989
glycolipids, blood group antigens on 362
glycophorins
A, U antibodies 512
B, U antibodies 512, 719
glycoprotein (GP)
blood group antigens on 366
Ibα dimorphism, Italy 891
IV-negative platelet phenotype, African Americans
and Asians 331
graft-versus-host disease, transfusion-associated
(TA-GVHD)
immunocompetent patients in Lebanon ..... 286(L)
neonates ..... 101(E), 117
target molecule of cytotoxic T cells ..... 846(L)
VATS 854
granulocyte–colony-stimulating factor (G-CSF)
blood counts and collection of PBPCs 160, 596
effects on normal donors 601, 611, 943
HBsAg false-positive 948
granulocyte-macrophage–colony-stimulating factor (GM–CSF),
PBPC mobilization 611
granulocytes
antigens, five ethnic groups 895
transfusions, alloimmunization and 1009

H

H, deficient phenotypes, Chinese in Hong Kong 994
Haemophilus influenzae, blood groups 362
HBV, see hepatitis B virus
HCV, see hepatitis C virus
HDN, see hemolytic disease of the newborn
He
expression and quantitation 719
glycophorin 512
heart surgery (open), pediatric, transfusion patterns 150
Helicobacter pylori blood groups 362
hematocrit
donor tolerance to red cell donation 674
G–CSF, and collection of PBPCs 596
rHuEPO and autologous blood donation 29
hematopoietic progenitor cells, see PBPCs
hemodilution, acute normovolemic (ANH)
adverse effects 641
benefits 641
cost-effectiveness ..... 849(L)
efficacy 640
hemoglobin
continuous reinfusion of whole blood,
unprocessed 648
donor tolerance to red cell donation 674
intraoperative bleeding, mathematical model for
minimizing loss 832
hemolysis
BMT with minor ABO incompatibility 71
drug-dependent, carboplatin-induced 1016
immune, antibody-mediated in AIHA 463
suction-induced at various vacuum pressures 57
hemolytic disease of the newborn (HDN) ..... 478(L), 938(L)
hemophilia
B, factor IX inhibitor in plasma detects factor IX 467
CMV AIDS and transfusion 681
hepatitis GB virus infection in Japan ..... 669(L)
parvovirus B19 and 238
recombinant factor VIII concentrates and
anaphylaxis 358
blood safety decisions, 1982-1986 ..... 919, 928
hemorrheologic conditions, HES and 450
hemostatic defects in the critically ill, invasive line
placement 827
hemotherapy, organ transplantation 263/764
heparin 798
hepatitis B
core (HBc) antigen, antibody to, and retroviral
infections 232
surface antigen (HBsAg)
false-positive in G–CSF recipient 948
antigenemia, post-vaccination ..... 386(L)
virus (HBV), infectivity model, photochemical
inactivation 406

hepatitis C
donor ALT and HBc antigen ... 776
pasteurized C1-inhibitor concentrate ... 84(L)
virus (HCV)
antibody screening ... 401, 581(L)
core antigen and crossreactive epitope ... 581(L)
genotype, and RIBA-3 ... 547
genotype prevalence, anti-HCV-positive donors ... 552
immunopathogenesis and prophylaxis ... 836
IVIG, contaminated ... 394
IVIG, Spain ... 725
RIBA diagnosis ... 476(L), 547
second- and third-generation, ELISA ... 477(L)
seroconversion ... 339
vaccination ... 836
hepatitis G virus, open heart surgery ... 836, 937(L)
hepatitis GB virus, Japanese hemophiliacs ... 669(L)
hepatitis non-A,non-B ... 836
hepatitis non-B,non-C, (NBNC) donor ALT and HBc antigen ... 776
hepatitis, viral, screening and Gilbert's syndrome ... 974
HES, see hydroxyethyl starch
hibridomas ... 197(E)
hip arthroplasties, red cell transfusion predictors ... 144
Hispanics, NA1/NA2 ... 895
history, privacy during donor interviews ... 456
HIV, see human immunodeficiency virus
HLA class I-eluted platelets ... 438
HLA-A*0207, frequencies among Chinese ... 818
HLA-DQ6, frequency in DAT-positive patients ... 979
home transfusions, patients' attitude ... 140
HPA, see platelet antigens, human
human immunodeficiency virus (HIV), see also AIDS
anti-HBc and ... 232
blood supply ... 919
donor deferral criteria, Thailand ... 242
inactivation by high hydrostatic pressure ... 475(L)
infection, prevention with p24 antigen testing ... 382(L)
passive immunotherapy in AIDS ... 734
phthalocyanine photosensitization in red cells ... 743
predonation interviews ... 124
test-indeterminate donors ... 37
type 1 (HIV-1) ... 398
activation after transfusion ... 860
antigen testing ... 203
false-positive Western blot ... 45
group O variant surveillance ... 398
type 2 (HIV-2), New York ... 731
VATS ... 854
human leukocyte clusters of differentiation, 1995 directory ... 268
human T-lymphotropic virus (HTLV)
anti-HBc and ... 232
sensitivity and specificity of four assays ... 344
hydrostatic pressure, inactivation of HIV ... 475(L)
hydroxyethyl starch (HES), plasma volume, hemorrheologic conditions, and coagulation ... 450
hypotensive reactions
platelet transfusion ... 852(E), 904
white cell-reduced plasma and angiotensin-converting enzyme inhibitor therapy ... 900

I

identification, patient–blood unit, bedside verification ... 216
IgG, see immunoglobulins
Ii blood group system ... 365
immune function
alterations ... 629
effector cells, purging normal from malignant cells in autologous transfusion ... 910
reactions ... 629
immune globulin, intravenous (IVIG), HCV-contaminated ... 394, 725
immunoblot assay, recombinant (RIBA), HCV infection ... 476(L), 547
immunodeficiency, severe combined, circulating red cells after BMT ... 314
immunoglobulins
D antibodies in pregnancy ... 500
G (IgG), virus inactivation ... 866
G2 autoanti-U, AIHA case ... 575
coexistent with IgA deficiencies in donors ... 256
immunosorbent assay, enzyme-linked (ELISA), HCV ... 477(L)
immunotherapy, passive, AIDS ... 734
India, transfusion-transmitted kala-azar ... 848(L)
infants
HDN caused by anti-Vw ... 938(L)
neonatal transfusions, AS-1 red cells ... 873
premature and multiply transfused, limiting donor exposure and waste ... 64
TA-GVHD ... 101(E), 117
very-low-birth-weight, AS-1 red cells ... 873
infection, transfusion-associated
autologous donation ... 635
Chagas' disease ... 227, 969
colorectal cancer surgery ... 1000
HCV ... 394
marker testing, mandatory for autologous blood donation ... 85(L)
parvovirus B19 and hemophilia ... 238
postoperative meta-analysis of randomized clinical trials ... 175
prevention ... 582(L)
transmission ... 628
see also particular bacteria, disease, protozoan, virus
infusible platelet membrane ... 536
Institute of Medicine, HIV in the blood supply ... 919, 928
instructions for authors ... 90
interleukins
3, PBPC mobilization ... 611
6, platelet transfusions ... 886
8
bedside white cell-reduction filter ... 707
Fy6 epitope and ... 421
plasma priming activity ... 133
International Society of Blood Transfusion (ISBT)
guidelines for white cell-reduced blood components ... 11
Platelet Serology Workshop, report ... 75

international blood banking, AABB and ..... 765(E)
Israel, national blood program 1019
Italy
national blood program 1019
threonine[145]/methionine[145] dimorphism in platelet GPIbα 891
IVIG, see immune globulin, intravenous

J
Japan
gene frequencies, platelet antigens on GPIIIa 813
hepatitis GB virus infection among hemophiliacs ..... 669(L)
national blood program 1019

K
kala-azar, transfusion-transmitted, India ..... 848(L)
Kell blood group system
genotyping 495
mutations 490
kininogen, platelet concentrates, white cell-reduction filters and ..... 939(L)
kinship analysis, sibship in any two persons 259
Knops blood group system ..... 293(E), 362, 517

L
laboratories, quality management system ..... 384(L)
leukapheresis, pediatric patients 879
leukemia
BMT and same-donor peripheral blood buffy coat 685
acute myelocytic, BMT and same-donor peripheral blood buffy coat 685
UVB-irradiated platelet concentrates 296
leukocytes, CD directory, 1995 268
Lewis blood group system 362
ligation-based typing, HPA systems 1 to 5 426
lipids, priming activity generated during storage of platelet concentrates 133
liposomes, extraction of A and B blood group antigens 966
liver transplantation, red cell salvage 646
lymphocytes, subset ranges and donation effect 559
lymphocytotoxicity
antibodies, granulocyte transfusions and alloimmunization 1009
flow cytometric platelet crossmatching vs 250

M
MAIPA, see monoclonal antibody-specific immobilization of platelet antigens assay
marrow reconstitution, allogeneic, using PBPCs ..... 585(E)
maximum surgical blood order schedule, self-service electronic blood banking 347
media
electrolyte solution vs ..... 476(L)
starches 450
methionine[145]/threonine[145], dimorphism in platelet glycoprotein Ibα, Italy 891
8-methoxypsoralen, HBV inactivation in platelet concentrates 409
Mexico, donors and *Trypanosoma cruzi* 227
microemboli
continuous reinfusion of whole blood, unprocessed 648
red cell salvage 647
molecular therapy, purging normal from malignant cells in autologous transfusion 910
monoclonal antibodies ..... 197(E)
anti-B reagents, acquired B antigen 351
anti-D
chronic autoimmune thrombocytopenic purpura 328
fetomaternal hemorrhage, quantification of 432
NB1 analysis 168
technology, CD directory, 1995 268
monoclonal antibody-specific immobilization of platelet antigens assay (MAIPA)
flow cytometric platelet crossmatching, vs 250
HPA systems 1 to 5 genotyping 426
multiple transfusions, premature infants, limiting donor exposure and blood waste 64
Mycoplasma pneumoniae blood groups 362

N
NA, five ethnic groups 895
NADPH oxidase, platelet concentrates, priming 133
Nak[a]-negative platelet phenotype, African Americans and Asians 331
National Heart, Lung, and Blood Institute information services 82
National Hemophilia Foundation (NHF), blood monitoring system ..... 86(L)
National Institutes of Health, acknowledgment of research sponsors 935
Native American, NA1/NA2 895
natural killer cells, cytotoxic mechanism in AIHA 463
NB1 antigen, specificity analysis using MoAbs 1B5 and 7D8 168
NBNC, see hepatitis, non-B,non-C
needle injury, neurologic 213
neonates, see infants
Netherlands, national blood program 1019
neutrophils
antibodies, granulocyte transfusions and alloimmunization 1009
antigens, gene frequencies, five ethnic groups 895
G-CSF effects 601
nomenclature ..... 197(E)
NS4, RIBA-3 and 547
nursing staff, self-service electronic blood banking 347

O
O–negative blood
availability of fresh, low-titer blood ..... 392(E)
red cells, use patterns and control 209
open heart surgery, hepatitis G virus, transfusion-transmitted ..... 937(L)
orthopedics, red cell salvage 645

overtransfusion, autologous donation 636

P

P blood group system 363
p24 antigen
cost-effectiveness ..... 382(L)
donor screening 203
testing for blood safety (correction) ..... 191(L)
PA-I lectin 113
packing, shipping, platelets 335
pancytopenia, pseudo-AHTR 460
papain, AHG tests compared with PEG 487
paraformaldehyde, bedside white cell reduction 322
parentage testing, sibship determination in any two persons 259
parvovirus B19
blood groups 363
hemophilia and 238
PAS 2, Plasma-Lyte A vs ..... 1033(L)
patients, see also identification
factors, transfusion predictors in hip arthroplasties 144
selection, autologous donation 633
PBPCs, see peripheral blood progenitor cells
PCR, see polymerase chain reaction
pediatric patients
autologous donation 634, 635
large-volume leukapheresis 879
open heart surgery and transfusion patterns 150
PEG, see polyethylene glycol
pepsin, virus inactivation 866
peripheral blood progenitor cells (PBPCs)
allogeneic marrow reconstitution ..... 585(E)
bacterial contamination 53, 782, 789
citrate anticoagulant in collections 798
flow cytometry for determination of CD34+ and CD34– cells 985
frozen storage, temperature, duration, container 303, 794
G–CSF effects 601, 943
blood counts and 596
harvesting ..... 476(L)
marrow reconstitution, mobilization and collection strategies 160, 611, 943
thrombocytopenia after collection ..... 668(L)
pH
bacterial contamination detection 989
platelet swirling phenomenon 128, 989
virus inactivation by pepsin 866
phlebotomy, autologous donation 636
photochemical inactivation, HBV in platelet concentrates 409
photosensitization, HIV inactivation in red cells 743
phthalocyanine
P. falciparum inactivation 543
photosensitization, HIV inactivation in red cell concentrates 743
P^k, PA-I lectin to distinguish from p 113
plasma
coronary artery bypass graft surgery transfusion requirements 521
derivatives, pool size, manufacture, and safety ..... 768(E), 770
icteric, Gilbert's syndrome 974
platelet-rich plasma concentrate preparation 751, 886
volume, HES and 450
white cell reduction from red cell concentrates 714
Plasma-Lyte A, PAS2 vs ..... 1033(L)
Plasmodium falciparum
blood groups and 362
inactivation with phthalocyanine 543
platelets
antibodies, and flow cytometric crossmatching 250
activation, reduction during storage 5
additive solutions, Plasma-Lyte A vs PAS2 ..... 1033(L)
antigens
GPIIIa, gene frequencies 813
HPA-1a-negative donor, ELISA 805
human (HPA), GPIbα, Italy 891
system 4, ASRA 809
systems 1 to 5, genotyping by multiplex PCR and ligation-based typing 426
typing, conference report 75
concentrates
bacterial contamination detection 989
HBV photochemical inactivation 406
lipids' priming activity during storage 133
random-donor, whole-blood vs single-donor apheresis 955
recovery of functional activity after storage 691
shipping system 335
stored 445, 691, 955
UV-B-irradiated, hematologic malignancy 296
white cell-reduction filters and kininogen ..... 939(L)
coronary artery bypass graft surgery transfusion requirements 521
crossmatching and platelet-reactive antibodies 250
factor 4, stored platelets 445
G–CSF effects 596, 601
HLA
class I-eluted 438
-reduced to overcome refractoriness ..... 388(E)
HPA-1a (PI^{A1})-negative, ELISA 805
increment, posttransfusion, antibiotics and 952
membrane, infusible microvesicles 536
Nak^a-negative phenotype, African Americans and Asians 331
production 751
refractoriness
antibiotics and body temperature 952
HLA-reduced platelets to overcome ..... 388(E)
storage and time-dependent release of bioactive substances 960
swirling phenomenon 128
bacterial contamination detection 989
transfusion
reactions 886, 900
substitute 536
undertransfusion 533
pneumonia, transfusion and colorectal cancer surgery 1000
policy, HIV in the blood supply 919, 928

polyethylene glycol (PEG)
AHG tests compared with enzyme-based antibody tests ... 487
autoadsorption for the detection of alloantibodies ... 384(L)
polymerase chain reaction (PCR)
HBV inactivation in platelet concentrates ... 409
multiplex, HPA systems 1 to 5 genotyping ... 426
neutrophil antigen gene frequencies, five ethnic groups ... 895
sensitivity and specificity for HTLV-I and -II ... 344
sequence-specific primers
HPA systems 1 to 5 genotyping ... 426
Kell blood group genotyping ... 495
pool size, plasma derivative safety ... 768(E)
pregnancy
autologous donation ... 634, 635, 637
E and e antigen deletion ... 191(L)
flow cytometric quantitation of D antibodies in serum ... 500
prewarmed tests ... 192(L)
privacy, donor health history interviews ... 456
procedures ... 200(E)
Pseudomonas aeruginosa lectin ... 113
Public Health Service, HIV in the blood supply ... 919, 928
pulmonary artery lines in critically ill ... 827
purging ... 910
purpura, chronic autoimmune thrombocytopenic, monoclonal anti-D ... 328

Q

quality control
cell processing ... 1(E), 53
component storage ... 470
test laboratories ... 384(L)

R

R_O^{Har} antigenic complex ... 478(L), 1034(L)
see also D
R_O^{Har}r Rh:33 mother, HDN ... 478(L)
RANTES, see T cells
bedside white cell-reduction filter ... 707
reagents
CD34+ and CD34– cell lines, preparation and thawing ... 985
DIDS, to prevent rouleaux formation ... 109
Recombinate, allergic reaction ... 358
record-keeping ... 200(E)
red cells
autoantibodies
anti-Di^b ... 802
sera antibodies and ... 481
chemokine receptor, Fy6 epitope and ... 421
circulating, bone marrow transplantation ... 314
concentrates, HIV inactivation with phthalocyanine photosensitization ... 743
coronary artery bypass graft surgery transfusion requirements ... 521
G–CSF effects, and collection of peripheral blood stem cells ... 596
H-deficient phenotypes among Chinese in Hong Kong ... 994
hemostatic effect of transfusion in anemia and thrombocytopenia ... 290(L)
O–, use patterns and control ... 209
reticulocytes, persistence in donor red cells ... 318
salvage, perioperative ... 644
undertransfusion ... 533
use Ontario hospitals ... 699
refrigeration, reticulocytes ... 318
regulations, HIV in the blood supply ... 919, 928
reinfusion devices, single unit ... 649
research sponsors, acknowledgment of NIH ... 935
respiratory tract symptoms, bacterial contamination after donor call-back ... 1035(L)
restriction fragment length polymorphisms, Kell blood group ... 490
reticulocytes
G–CSF effects ... 601
persistence in donor red cells ... 318
reticulocytopenia, AIHA case ... 575
Rh blood group system ... 191(L), 506, 567
rHuEPO see erythropoietin, recombinant human
RIBA, see immunoblot assay, recombinant
risk
avoidance ... 629
benefit ... 629
factors, self-exclusion and, HIV ... 124
perception, home transfusions ... 140
transfusion ... 628
rouleaux formation, DIDS and ... 109

S

Scotland, national blood program ... 1019
screens, donor privacy during health history interviews ... 456
Secretor gene nonsense mutation, search ... 286(L)
self-exclusion, HIV ... 124
sepsis, see also contamination; infection
continuous reinfusion of whole blood, unprocessed ... 648
gram-negative bacteria of the urinary tract, pseudo-AHTR ... 460
Ser103, G epitope formation ... 506
seroconversion, HCV ... 339
serologic testing, pretransfusion, chloramphenicol-dependent antibody ... 187
serum antibodies, flow cytometric quantitation in pregnancy ... 500
shipping system, platelet components ... 335
sibship, determination in any two persons ... 259
South America, donors and *Trypanosoma cruzi* ... 227
soybean lectin, to distinguish from P^k from p ... 113
Spain, HCV infection among recipients of IVIG ... 725
standard operating procedures, white cell-reduced blood ... 11
standardization ... 200(E)
starches, plasma volume, hemorrheologic conditions, and coagulation ... 450
stem cell factor, PBPC mobilization ... 611

storage, see also freezing; refrigeration
platelet concentrates
chemokines in ... 445
lipids' priming activity during storage ... 133
recovery of functional activity ... 691
platelets, suspended bag–buffy coat technique ... 5
time
white cell- and platelet-derived bioactive substances ... 960
white cell reduction from red cell concentrates ... 714
surgery
colorectal cancer, transfusion and infection ... 1000
electronic blood banking for compatible blood ... 347
Swann blood group polymorphism ... 419
Sweden, national blood program ... 1019
swirling
bacterial contamination detection ... 989
platelet phenomenon ... 128
Switzerland, national blood program ... 1019
S–s–
He and ... 719
U antibodies ... 512

T

TA-GVHD, see graft-versus-host disease, transfusion associated
Taiwan, national blood program ... 1019
T cells
regulated upon activation (RANTES), stored platelets ... 445
target molecule in TA-GVHD ... 846(L)
temperature
body, platelet increment posttransfusion and ... 952
freezing, PBPCs ... 303
shipping, platelet components ... 335
storage
components ... 470
white cell reduction from red cell concentrates ... 714
threonine^{145}/methionine^{145}, dimorphism in platelet GPIbα, Italy ... 891
thrombocytopenia
continuous reinfusion of whole blood, unprocessed ... 648
hemostatic effect of red cell transfusion ... 290(L)
PBSC collection ... 668(L)
red cell salvage ... 646
use of infusible platelet membrane in ... 536
β-thromboglobulin, stored platelets ... 445
training, in-service videotape, transfusion medicine principles ... 739
transfusion reactions
allergic ... 21, 629
hemolytic
fatal ABO mistyping ... 351
acute (AHTR), pseudo- ... 460
febrile nonhemolytic, platelets (single-donor apheresis) vs random-donor platelets ... 21
white cell-reduced components ... 21
transfusion
autologous, Consensus Development Conference ... 589(E)
coronary artery bypass graft surgery ... 521
errors
fatal ABO mistyping ... 351
prevention with and cost-effectiveness of barrier system ... 222
future ... 630
out-of-hospital, patients' attitude ... 140
overtransfusion, autologous donation ... 636
practice ... 629
predictors, hip arthroplasties ... 144
related activities, AABB questionnaire ... 375
substitutes, platelet membrane, infusible microvesicles ... 536
undertransfusion, monitoring for ... 533
transfusion-associated diseases, see also contamination; infection, transfusion-associated; particular disease name
AABB questionnaire ... 377
Chagas' disease ... 227, 969
kala-azar ... 848(L)
transplantation, solid organ, institutional variation ... 263/764
trauma, red cell salvage ... 645
Trypanosoma cruzi
blood groups ... 227, 369

U

U, variant antibodies ... 512
ultraviolet (UV) light
A, HBV inactivation in platelet concentrates ... 409
B, platelet concentrate irradiation ... 296
red, HIV inactivation ... 743
umbilical cord blood, questions ... 288(L)
undertransfusion, monitoring for ... 533
United States, national blood program ... 1019
urinary tract infection, transfusion and colorectal cancer surgery ... 1000
urosepsis, acute gram-negative, pseudo-AHTR ... 460

V

vaccination, HBsAg after ... 384(L)
vacuum pressure, hemolysis and ... 57
vascular surgery, red cell salvage ... 646
venous line (central) placement in the critically ill, hemostatic defects and ... 827
videotapes, in-service training, transfusion medicine principles ... 739
Viral Activation Transfusion Study (VATS) ... 854
viruses, see also particular virus name
blood groups as incidental receptors ... 362
inactivation by pepsin at pH 4 of IgG solutions ... 866
von Willebrand factor antigen, ristocetin cofactor, HES ... 450
Vw, antibody causing HDN ... 938(L)

W

Wales, national blood program ... 1019
Western blot
HIV-1, false-positive ... 45
HTLV-I and -II ... 344

white cell-reduced plasma, hypotensive reactions in a patient undergoing angiotensin-converting enzyme inhibitor therapy 900
white cell reduction
bedside filtration 322
component storage 470
cost-effectiveness ..... 582(L)
filters, platelet concentrates and kininogen and ..... 939(L)
white cells
antibody screening 1009
filtration from red cell concentrates 707, 714
fragments, component storage 470
G–CSF effects, and collection of PBPCs 596
storage and time-dependent release of bioactive substances 960
whole blood
plasma-reduced, storage and release of bioactive substances 960
random-donor, vs single-donor apheresis for platelet concentrates 955
storage and release of bioactive substances 960
unprocessed, continuous reinfusion 648
wound infection, transfusion and colorectal cancer surgery 1000